Panel Discussion: Reflecting on Past Successes & Future Challenges Across the T-Cell Engager Landscape to Assess the Benchmark for Success & Accelerate TCEs to Patients

• Reflecting on the move away from first generation BiTE molecules to next-generation logic-gated and multi-specific T cell engagers
• Exploring advancements in preclinical and clinical modelling of TCEs to allow for improvements in efficacy whilst minimizing system toxicity
• Evaluating the potential for TCEs to serve as a scalable, off-the-shelf alternative to personalized CAR-T therapies

Speakers:

Saso Cemerski

Executive Director & Head of Immune Engagers

AstraZeneca

Jonah Rainey

Associate Vice President

Eli Lilly & Co.

Jennifer Towne

Executive Vice President & Chief Scientific Officer

Vir Biotechnology Inc.

Alison Crawford

Director of Immuno-oncology

Regeneron Pharmaceuticals